Human papillomavirus genotype distributions: implications for vaccination and cancer screening in the United States.
about
American Cancer Society, American Society for Colposcopy and Cervical Pathology, and American Society for Clinical Pathology screening guidelines for the prevention and early detection of cervical cancerAmerican Cancer Society, American Society for Colposcopy and Cervical Pathology, and American Society for Clinical Pathology screening guidelines for the prevention and early detection of cervical cancer.Are the currently existing anti-human papillomavirus vaccines appropriate for the developing world?HPV genotypes in high grade cervical lesions and invasive cervical carcinoma as detected by two commercial DNA assays, North Carolina, 2001-2006Age-specific prevalence of HPV16/18 genotypes in cervical cancer: A systematic review and meta-analysis.Human papillomavirus genotype-specific prevalence across the continuum of cervical neoplasia and cancer.No evidence for synergy between human papillomavirus genotypes for the risk of high-grade squamous intraepithelial lesions in a large population-based study.Type-specific prevalence of high-risk human papillomavirus by cervical cytology and age: Data from the health check-ups of 7,014 Korean women.Individual detection of 14 high risk human papilloma virus genotypes by the PapType test for the prediction of high grade cervical lesions.Cervical cytology and multiple type HPV infection: a study of 8182 women ages 31-65Cervical Cancers Manifest a High Rate of Infection by a High-Risk Human Papilloma Virus Subtype but a Very Low Rate of Infection by a Low-Risk Subtype in the Guiyang District of China.Type distribution of human papillomavirus among adult women diagnosed with invasive cervical cancer (stage 1b or higher) in New Zealand.Human papillomavirus genotypes in cervical intraepithelial neoplasia grade 3An updated natural history model of cervical cancer: derivation of model parameters.Clinical and pathological heterogeneity of cervical intraepithelial neoplasia grade 3.HPV type-related chromosomal profiles in high-grade cervical intraepithelial neoplasia.The role of co-factors in the progression from human papillomavirus infection to cervical cancerImportance of HPV Genotyping for the Screening, Therapy and Management of Cervical NeoplasiasImmunogenicity of bivalent human papillomavirus DNA vaccine using human endogenous retrovirus envelope-coated baculoviral vectors in mice and pigs.[Molecular diagnosis of HPV infections].Human papillomavirus testing in the prevention of cervical cancerReassessing target antigens for adoptive T-cell therapy.Prevalence of human papillomavirus types in invasive cervical cancers from 7 US cancer registries before vaccine introduction.Is human papillomavirus genotype an influencing factor on radiotherapy outcome? Ambiguity caused by an association of HPV 18 genotype and adenocarcinoma histology.Human papillomavirus prevalence in a population of women living in Port-au-Prince and Leogane, HaitiAge-specific occurrence of HPV16- and HPV18-related cervical cancer.Natural history of progression of HPV infection to cervical lesion or clearance: analysis of the control arm of the large, randomised PATRICIA study.Human papillomavirus (HPV) genotypes in women with cervical precancer and cancer at Kaiser Permanente Northern California.Changing pattern of epithelial cell abnormalities using revised Bethesda systemA long-term prospective study of type-specific human papillomavirus infection and risk of cervical neoplasia among 20,000 women in the Portland Kaiser Cohort Study.A chimeric 18L1-45RG1 virus-like particle vaccine cross-protects against oncogenic alpha-7 human papillomavirus types.Prevalence and Distribution of High-Risk Genotypes of HPV in Women with Severe Cervical Lesions in Madrid, Spain: Importance of Detecting Genotype 16 and Other High-Risk Genotypes.Comparing bivalent and quadrivalent human papillomavirus vaccines: economic evaluation based on transmission model.A new arylbenzofuran derivative functions as an anti-tumour agent by inducing DNA damage and inhibiting PARP activity.Detection of HPV DNA in paraffin-embedded cervical samples: a comparison of four genotyping methodsB3GNT3 Expression Is a Novel Marker Correlated with Pelvic Lymph Node Metastasis and Poor Clinical Outcome in Early-Stage Cervical Cancer.Evolution of cervical cancer screening and prevention in United States and Canada: implications for public health practitioners and clinicians.Cost-effectiveness of using human papillomavirus 16/18 genotype triage in cervical cancer screening.Improving compliance with cervical cancer screening guidelines.Immunogenicity of quadrivalent human papillomavirus vaccine in organ transplant recipients.
P2860
Q24607403-C7FAC47E-6549-4ECE-AB9E-F0172BB87476Q26828840-D472043B-6A7B-4584-8B48-011008A9A9B3Q27692056-EDDE306F-9280-4711-888C-F3AACFA2CA59Q28730863-EB82F5C1-2D6B-4712-9217-5036ED62A7CCQ30252012-E6F2267D-48EC-4202-891D-8C5711BA21C7Q30301333-65551330-C177-4301-AB86-6B8A066B467DQ30407482-0D78FD1C-4057-4960-8A16-018336791D67Q30712681-0ECCCAAC-743C-4AAE-8ADF-68BEB8C956CCQ33574454-9B59ABE0-8722-47D8-925C-6A12421850CBQ33693366-4CC177D1-780D-4146-B7AD-A21B54FF7721Q33776749-1C4E8C33-F9E7-4869-A43C-0DB1B995BAB6Q33904416-9428DE91-3E14-455A-8C0E-87B504243878Q33984185-D1A9C4EF-D2BD-4283-990A-55BDEFB0C1C0Q34083083-7C57E00F-483F-49D1-A268-F24B8438BE9EQ34130333-D3091B65-5EDF-41B0-9DBB-19A2ABBF5844Q34138292-099F1BE1-C169-4266-A94D-D25115744552Q34311313-13CBDE0B-F1D9-4C83-998A-CA91A7E24226Q34432811-FEB9F0B2-2724-4F9D-9124-14589DBAB555Q34500100-F9963340-2DD0-4600-9029-83217E7207AAQ34543310-BAF985D9-6AB2-4E18-A8E2-C385642CEF62Q34616083-65B0F728-6452-4C9C-8DD5-749F5F7180BFQ34789569-50BC98EF-D0A8-4A05-A85A-58C81B884092Q34955292-31561A69-D27F-4738-9C0B-5BBB199BFAA8Q34990478-AF0B7881-6F36-449D-A374-C2A7F17C2230Q35009255-BCCB9289-2404-451E-820D-1713A69797BFQ35013844-AE87E88D-3754-4D59-A73D-F2F6F77AE000Q35048280-D7B47722-44EB-45A5-BE19-01B7466BAC59Q35051454-5D40A4C3-F44D-4EBD-A617-60074F7876A9Q35123076-23FE67FB-D28C-4D00-9C2D-54A9844AAC1FQ35164373-2C57DF58-1825-448C-9893-E027EE8AD28DQ35196119-04FEDDE3-A6AA-4059-9F10-E0C250078301Q35203337-68203096-1603-4EF5-9DD2-5536217165A7Q35235306-375270B4-E259-444B-B75D-8663C33404FCQ35681896-8EC7B95C-CEB5-42E4-B52E-6F9D52D67CBAQ35852900-81D22EED-482E-4A35-AA6D-D35FB01385F4Q35879359-2D84108F-C24B-48D3-937C-BDE3D8B4AF4AQ35889801-F1D18C66-9923-4C0D-8F5D-F1E8481C0730Q36057298-394E1F3C-CD5B-4762-845B-335608B7AE4EQ36058295-A0CF41BC-F89A-4D10-B095-CE519CD95A13Q36093327-E3908CD0-6172-4F02-AFD0-86044B8AABC0
P2860
Human papillomavirus genotype distributions: implications for vaccination and cancer screening in the United States.
description
article científic
@ca
article scientifique
@fr
articolo scientifico
@it
artigo científico
@pt
bilimsel makale
@tr
scientific article published on 24 March 2009
@en
vedecký článok
@sk
vetenskaplig artikel
@sv
videnskabelig artikel
@da
vědecký článek
@cs
name
Human papillomavirus genotype ...... creening in the United States.
@en
Human papillomavirus genotype ...... creening in the United States.
@nl
type
label
Human papillomavirus genotype ...... creening in the United States.
@en
Human papillomavirus genotype ...... creening in the United States.
@nl
prefLabel
Human papillomavirus genotype ...... creening in the United States.
@en
Human papillomavirus genotype ...... creening in the United States.
@nl
P2093
P2860
P356
P1476
Human papillomavirus genotype ...... creening in the United States.
@en
P2093
Charles R Key
Nancy E Joste
Philip E Castle
William C Hunt
Wim G V Quint
P2860
P304
P356
10.1093/JNCI/DJN510
P407
P577
2009-03-24T00:00:00Z